Dosing patterns and dose effects of sacubitril/valsartan: A claims-based retrospective cohort study
Most individuals initiate and remain on the lowest SAC/VAL dose despite guidelines to titrate upward. SAC/VAL dosage is significantly associated with outcomes, with higher doses associated with more clinical and cost benefits. Research is needed to identify barriers to dose titration and to develop interventions for maximal patient benefit.
Authors
- Shannon B. Richards (ORCID: https://orcid.org/0000-0002-6278-8388)
- Tyson S. Barrett (ORCID: https://orcid.org/0000-0002-2137-1391)
- Amresh Raina
- Lawrence I. Sinoway (ORCID: https://orcid.org/0000-0001-9053-5153)
- Keith LeJeune
- Jillian M. Rung (ORCID: https://orcid.org/0000-0002-5945-6454)
Institutions
- Pennsylvania State University (US)
- Allegheny Health Network (US)
- Allegheny General Hospital (US)
- Highmark Blue Cross Blue Shield (US)
- Penn State Milton S. Hershey Medical Center (US)
Publication Details
- Journal
- PLoS ONE
- Published
- 2025-03-25
- DOI
- https://doi.org/10.1371/journal.pone.0320216
- Citations
- 2
- Primary Topic
- Heart Failure Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 2.78